Specific Cancer Stem Cell-therapy by Albumin Nanoparticles Functionalized with CD44-mediated Targeting
Overview
Authors
Affiliations
Background: Cancer stem cells (CSCs) are highly proliferative and tumorigenic, which contributes to chemotherapy resistance and tumor occurrence. CSCs specific therapy may achieve excellent therapeutic effects, especially to the drug-resistant tumors.
Results: In this study, we developed a kind of targeting nanoparticle system based on cationic albumin functionalized with hyaluronic acid (HA) to target the CD44 overexpressed CSCs. All-trans-retinoic acid (ATRA) was encapsulated in the nanoparticles with ultrahigh encapsulation efficiency (EE%) of 93% and loading content of 8.37%. TEM analysis showed the nanoparticles were spherical, uniform-sized and surrounded by a coating layer consists of HA. Four weeks of continuously measurements of size, PDI and EE% revealed the high stability of nanoparticles. Thanks to HA conjugation on the surface, the resultant nanoparticles (HA-eNPs) demonstrated high affinity and specific binding to CD44-enriched B16F10 cells. In vivo imaging revealed that HA-eNPs can targeted accumulate in tumor-bearing lung of mouse. The cytotoxicity tests illustrated that ATRA-laden HA-eNPs possessed better killing ability to B16F10 cells than free drug or normal nanoparticles in the same dose, indicating its good targeting property. Moreover, HA-eNPs/ATRA treatment decreased side population of B16F10 cells significantly in vitro. Finally, tumor growth was significantly inhibited by HA-eNPs/ATRA in lung metastasis tumor mice.
Conclusions: These results demonstrate that the HA functionalized albumin nanoparticles is an efficient system for targeted delivery of antitumor drugs to eliminate the CSCs.
Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).
PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.
Sun S, Yang Q, Jiang D, Zhang Y J Nanobiotechnology. 2024; 22(1):176.
PMID: 38609981 PMC: 11015566. DOI: 10.1186/s12951-024-02432-5.
Eradicating the tumor "seeds": nanomedicines-based therapies against cancer stem cells.
Li L, Ni R, Zheng D, Chen L Daru. 2023; 31(1):83-94.
PMID: 36971921 PMC: 10238364. DOI: 10.1007/s40199-023-00456-0.
Alshammari M, Almomen E, Alshahrani K, Altwalah S, Kamal M, Al-Twallah M Biomedicines. 2023; 11(2).
PMID: 36831009 PMC: 9952953. DOI: 10.3390/biomedicines11020473.
Choi H, Lim J, Kang T, Chung B Antioxidants (Basel). 2022; 11(11).
PMID: 36358509 PMC: 9686543. DOI: 10.3390/antiox11112137.